Understand the source comparison
Follistatin-344 Myostatin/Activin Binding: Mechanism Comparison
Understanding how follistatin-344 myostatin/activin binding compares to other myostatin inhibitors clarifies why it remains the gold standard in muscle growth research despite the availability of monoclonal antibodies and receptor decoys. Follistatin-344 Myost
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how follistatin-344 myostatin/activin binding compares to other myostatin inhibitors clarifies why it remains the gold standard in muscle growth research despite the availability of monoclonal antibodies and receptor decoys.
- Follistatin-344
- Myostatin + Activin A
- 200–500 pM (myostatin), 500 pM–1 nM (activin)
- Neutralizes both ligands with high affinity
- HSPG-mediated tissue localization sustains muscle-specific action for days
- Dual-target inhibition with extended tissue residence makes follistatin-344 the most physiologically relevant myostatin inhibitor for chronic muscle wasting models
- Anti-Myostatin mAb (e.g., LY2495655)
- Myostatin only
- 50–200 pM
- Highly specific—does not bind activin
- Systemic circulation with 2–3 week half-life
- Selective myostatin blockade is useful when activin signaling must remain intact, but misses inflammatory cachexia driven by activin A
- ActRIIB-Fc Decoy Receptor
- Myostatin, Activin A, GDF11, BMP9/10
- 10–100 pM (promiscuous binding)
- Non-selective—binds multiple TGF-β superfamily ligands
- Circulates systemically, no tissue retention mechanism
- Potent but non-specific—off-target BMP inhibition causes adverse cardiovascular effects in clinical trials
- Follistatin-288
- Identical ligand binding to follistatin-344
- No HSPG binding—rapid renal clearance, 2–3 hour half-life
- Equivalent binding affinity but insufficient tissue retention for sustained muscle anabolism—better suited for acute systemic studies
- The comparison makes the trade-off explicit: follistatin-344 myostatin/activin binding sacrifices systemic reach for tissue-specific persistence. This is a feature, not a limitation—muscle wasting is a local tissue pathology, and sustained inhibitor presence at the site of myostatin secretion produces more robust hypertrophy than intermittent systemic exposure. Research from the University of Pennsylvania published in PNAS showed that continuous follistatin-344 expression via AAV gene therapy produced 35% greater muscle mass gains than weekly bolus injections of follistatin-288 delivering equivalent total protein exposure, purely due to the difference in tissue pharmacokinetics.